Frontier Pharma: Pancreatic Cancer Market - Identifying and Commercializing First-in-Class Innovation: 447 therapeutics in active development across all phases

Jul 15, 2015, 10:21 ET from Research and Markets

DUBLIN, July 09, 2015 /PRNewswire/ --

Research and Markets ( has announced the addition of the "Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation" report to their offering.

While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the early stages, meaning a significant proportion of therapies are unlikely to reach the market in the near future, according to this report.

The report states that while the pancreatic cancer treatment pipeline contains 447 therapeutics in active development across all phases, compared to 209 currently-marketed products, almost 75% of therapies are in phase I or earlier.

According to the latest research, 58% of drugs in the pancreatic cancer treatment pipeline are in the discovery or preclinical stages, 17% are in phase I and 21% are in phase II, leaving just 4% of products in phase III of development.

The report adds that the high level of first-in-class development in pancreatic cancer therapeutics is a promising sign of the industry seeking innovative treatment solutions.

The report also states that while the current global treatment market for pancreatic cancer is comprised of 91% small molecules and 9% biologics, some 41% of the pipeline is formed from biologic therapies.

This report analyzes innovation in pancreatic cancer treatment in the context of the overall pipeline and current market landscape. It also provides details on the deals landscape surrounding first-in-class products in pancreatic cancer therapeutics, and pinpoints opportunities for in-licensing.

Key Topics Covered:

1 Tables & Figures

2 Executive Summary

3 The Case for Innovation

4 Clinical and Commercial Landscape

5 Assessment of Pipeline Product Innovation

6 Signaling Network, Disease Causation and Innovation Alignment

7 First-in-Class Target Evaluation

8 Deals and Strategic Consolidations

9 Appendix

For more information visit

Media Contact: Laura Wood , +353-1-481-1716,

SOURCE Research and Markets